Linerixibat reduces itch, improves sleep in PBC Phase 3 trial
Nearly six months of treatment with the experimental oral candidate linerixibat significantly reduced itch and itch-related sleep problems for adults with primary biliary cholangitis…
Cholangitis
Even with past treatment, Livdelzi works on primary biliary cholangitis
The efficacy of Livdelzi (seladelpar) at treating primary biliary cholangitis (PBC) is similar irrespective of whether patients previously received other medications, according to…
RTY-694 shows promise in models of liver, bile duct diseases PFIC, PSC
An experimental oral therapy by Rectify Pharmaceuticals called RTY-694 reduced markers of slowed bile flow and inflammation in a mouse model of progressive…
New primary sclerosing cholangitis treatment to target ACLY enzyme
With ESP-1336 as their lead candidate, Esperion Therapeutics is developing new treatments for primary sclerosing cholangitis (PSC) by targeting an enzyme called ACLY.
New Phase 2 trial data show benefits of elafibranor for PSC
Daily treatment with Ipsen’s elafibranor safely and effectively eases itching, stabilizes liver scarring, and reduces liver damage biomarkers in adults with primary sclerosing…
High IgG levels at diagnosis tied to worse PBC outcomes: Study
High blood levels of the antibody immunoglobulin G, or IgG, at diagnosis are linked to a more severe disease course among people with primary…
American Liver Foundation gears up for advocacy summit
Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…
Focus of World Liver Day this April 19 is role of diet in liver health
Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…
Scotland to cover Iqirvo for eligible primary biliary cholangitis patients
The Scottish Medicines Consortium (SMC) has agreed that Ipsen’s Iqirvo (elafibranor) be covered by the country’s public National Health Service (NHS), making the therapy…
Nebokitug shows sustained benefits for moderate, advanced PSC
A year of treatment with Chemomab Therapeutics’s candidate nebokitug reduces key disease biomarkers and the occurrence of clinical events that reflect disease progression among…
